Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A.

J Hematol Oncol. 2016 Mar 10;9:23. doi: 10.1186/s13045-016-0254-5.

2.

PRL-3 activates mTORC1 in Cancer Progression.

Ye Z, Al-Aidaroos AQ, Park JE, Yuen HF, Zhang SD, Gupta A, Lin Y, Shen HM, Zeng Q.

Sci Rep. 2015 Nov 24;5:17046. doi: 10.1038/srep17046.

3.

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.

Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, Valk PJ, Zhang SD, Chng WJ, Hong CW, Mills K, Zeng Q.

EMBO Mol Med. 2013 Sep;5(9):1351-66. doi: 10.1002/emmm.201202183. Epub 2013 Aug 8.

Supplemental Content

Loading ...
Support Center